Clinical TrialsThe accelerated Deep TMS protocol resulted in outcomes comparable to the standard once-daily TMS protocol while requiring considerably fewer visits to the clinic.
Financial PerformanceThe company recorded $11.4M in top-line revenue, beating our forecast of $10.7M.
Market ExpansionBrainsWay received expanded FDA labeling for Deep TMS to treat late-life depression, increasing the upper age limit from 68 to 86 years, thus broadening the availability of Deep TMS therapy.